BSE filing, NSE: VIVIMEDLAB. Summary written from the filing by ALFA Finder's alert engine.
Vivimed Labs Ltd: key numbers
- Share price
- ₹5.75
- Market cap
- ₹47.68 Cr
- Revenue (annual)
- ₹69.99 Cr
- Net profit (annual)
- ₹-176.5 Cr
- P/E (TTM)
- -0.3×Sector 46.1×
- Promoter holding
- 7.57%-0.20% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivimed Labs Ltd
All →Vivimed Labs Insolvency Petition
Vivimed Labs Limited, currently under CIRP, has scheduled the 8th meeting of the Committee of Creditors for September 29, 2026, via audio-visual means.
Vivimed Labs Other Announcement
Vivimed Labs Limited, currently under corporate insolvency resolution, has announced its 7th Committee of Creditors meeting scheduled for September 10, 2026, to be held virtually.
Vivimed Labs Insolvency Petition
Vivimed Labs, undergoing CIRP, has scheduled the 6th meeting of the Committee of Creditors for August 18, 2026, as per regulatory requirements.
Vivimed Labs Q4 FY26 Results: Net Loss of ₹147.1 Cr, Loss Widens
Vivimed Labs Ltd reported revenue from operations of ₹12 Cr (-53.1% YoY) and a net loss of ₹147.1 Cr for Q4 FY26.
- Key figure
- Net loss ₹147.1 Cr
Vivimed Labs Board Meeting Date
Vivimed Labs scheduled a board meeting on July 17, 2026. The board will consider audited financial results for the period ending March 31, 2026.
Vivimed Labs Results Correction
Vivimed Labs replied to NSE's clarification request regarding financial results. The company submitted a revised Statement of Impact of audit qualifications.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.